Oncolytics Biotech Inc T.ONC

ONCY Initiates New Pancreatic Cancer GOBLET Cohort

[Noteable]

SAN DIEGO and CALGARY, AB, March 5, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced it has submitted an amendment to GOBLET to initiate a new Phase 1/2 cohort evaluating pelareorep in combination with modified FOLFIRINOX (mFOLFIRINOX) with and without atezolizumab (Tecentriq®) in patients with newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC). This amendment will be reviewed by the Paul Ehrlich Institute (PEI; Germany's regulatory body) for approval before patient enrollment can begin. The cohort, the fifth of the GOBLET gastrointestinal cancer study, is being supported by the US$5 million Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN), an innovative program established to accelerate the development of new treatments for pancreatic cancer. Evaluation of this novel treatment approach will complement Oncolytics' ongoing development of pelareorep, atezolizumab, gemcitabine, and nab-paclitaxel in PDAC, which is expected to advance to a registrational study later this year.

US$5M grant supports study of pelareorep in combination with modified FOLFIRINOX +/- atezolizumab

Testing with the most common therapies could facilitate broad use of pelareorep in pancreatic cancer patients

https://stockhouse.com/news/press-releases/2024/03/05/oncolytics-biotech-xae-files-amendment-to-initiate-new-pancreatic-cancer-goblet/

[13X2413]

Stop regurgitating historical info. We need something fresh, new and exciting. Settle down bot.  

[Noteable]

Gastrointestinal Cancers and the GOBLET study cohorts Pancreatic Cancer Survival Data Reported at ESMO Supports Decision to Move to Phase 3: Updated data presented at the European Society for Medical Oncology (ESMO) Congress 2023 showed a 62% objective response rate, nearly triple what has been seen in historical control trials. In addition, interim survival data, including median

[Noteable]

August 30, 2024 - Tumor microenvironment: recent advances in immunotherapies of pancreatic cancer This yet-to-be published review focuses on the significance importance of the tumor microenvironment and the promising roles of immunotherapies in pancreatic cancer. https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1404025/abstract https://stockhouse.com/news/the-market